Summary
Endoscopy, Urology, and Pelvic Health segments are proving to be major growth drivers for Boston Scientific in 2018.
Neuromodulation is an underserved and underappreciated target market for Boston Scientific in 2018.
Boston Scientific has emerged as one of the leading players in Rhythmia and Electrophysiology business.
The company is a leading player in the peripheral interventions segment in 2018.
Retail investors, however, cannot ignore certain company-specific risks.
Lately, Boston Scientific (BSX) seems to be in the news for all the right reasons. While the recent news of acquisition of the company by Stryker (NYSE:SYK) proved to be a rumour, other news updates for the company about its clinical trials, acquisition strategy, restructuring initiatives, and emerging market performance have been mostly positive. The 2-year suspension of the medical device tax by U.S. House and Senate, starting January 2018, has also provided temporary relief to the company, allowing it to make resources available for its future R&D programs.
In this article, I plan to explain in greater detail why Boston Scientific is a buy opportunity in 2018.

